Treatment Options in Prostate Cancer Once Primary Therapy Fails

Catalona, 1994, 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer, J Urol, 152, 1837, 10.1016/S0022-5347(17)32397-2 Kupelian, 1997, Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy, Int J Radiat Oncol Biol Phys, 37, 1043, 10.1016/S0360-3016(96)00590-1 Pound, 1999, Natural history of progression after PSA elevation following radical prostatectomy, JAMA, 281, 1591, 10.1001/jama.281.17.1591 Jhaveri, 1999, Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results, Urology, 54, 884, 10.1016/S0090-4295(99)00252-6 Freedland, 2005, Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy, JAMA, 294, 433, 10.1001/jama.294.4.433 McLeod, 1997, Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer, Oncologist, 2, 18, 10.1634/theoncologist.2-1-18 Klotz, 2004, A re-assessment of the role of combined androgen blockade for advanced prostate cancer, BJU Int, 93, 1177, 10.1111/j.1464-410x.2004.04803.x Bolla, 2005, Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911), Lancet, 366, 572, 10.1016/S0140-6736(05)67101-2 Stephenson AJ, Pollack A, Scardino PT, et al. A nomogram to predict the outcome of salvage radiotherapy (RT) for biochemical recurrence (BCR) following radical prostatectomy. Presented at 101st annual meeting of the American Urological Association, Atlanta, GA, 20–25 May (abstract no. 1192). Stephenson, 2004, Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy, JAMA, 291, 1325, 10.1001/jama.291.11.1325 Moul, 2004, Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy, J Urol, 171, 1141, 10.1097/01.ju.0000113794.34810.d0 Gillatt, 2007, Preface, Eur Urol Suppl, 6, 325, 10.1016/j.eursup.2006.11.001 Bolla, 2002, Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial, Lancet, 360, 103, 10.1016/S0140-6736(02)09408-4 D’Amico, 2004, 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial, JAMA, 292, 821, 10.1001/jama.292.7.821 Messing, 2006, Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy, Lancet Oncol, 7, 472, 10.1016/S1470-2045(06)70700-8 Pilepich, 2005, Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31, Int J Radiat Oncol Biol Phys, 61, 1285, 10.1016/j.ijrobp.2004.08.047 McLeod, 2006, Bicalutamide 150mg plus standard care versus standard care alone for early prostate cancer, BJU Int, 97, 247, 10.1111/j.1464-410X.2005.06051.x Katz, 2003, Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer, J Clin Oncol, 21, 483, 10.1200/JCO.2003.12.043 Pearce, 2006, Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy, Int J Radiat Oncol Biol Phys, 65, 78, 10.1016/j.ijrobp.2005.11.041 Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006:CD006019. Eng, 2002, Primary radiation therapy for localized prostate cancer, Urol Oncol, 7, 239, 10.1016/S1078-1439(02)00198-9 Zelefsky, 2006, Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer, J Urol, 176, 1415, 10.1016/j.juro.2006.06.002 Sandler, 2000, Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy, Int J Radiat Oncol Biol Phys, 48, 629, 10.1016/S0360-3016(00)00717-3 Roach, 2006, Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference, Int J Radiat Oncol Biol Phys, 65, 965, 10.1016/j.ijrobp.2006.04.029 D’Amico, 2003, Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy, J Natl Cancer Inst, 95, 1376, 10.1093/jnci/djg043 Seltzer, 1999, Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer, J Urol, 162, 1322, 10.1016/S0022-5347(05)68277-8 Bader, 2002, Is a limited lymph node dissection an adequate staging procedure for prostate cancer?, J Urol, 168, 514, 10.1016/S0022-5347(05)64670-8 Keane, 2006, The emergence of radioimmunoscintigraphy for prostate cancer, Rev Urol, 8, S20 de Jong, 2003, 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer, Eur Urol, 44, 32, 10.1016/S0302-2838(03)00207-0 Catton, 2003, Salvage radiotherapy following radical prostatectomy, World J Urol, 21, 243, 10.1007/s00345-003-0360-1 Lee, 1997, Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations, J Clin Oncol, 15, 230, 10.1200/JCO.1997.15.1.230 Beyer, 2003, Brachytherapy for recurrent prostate cancer after radiation therapy, Semin Radiat Oncol, 13, 158, 10.1016/S1053-4296(03)70009-5 Beyer, 1999, Permanent brachytherapy as salvage treatment for recurrent prostate cancer, Urology, 54, 880, 10.1016/S0090-4295(99)00241-1 Grado, 1999, Salvage brachytherapy for localized prostate cancer after radiotherapy failure, Urology, 53, 2, 10.1016/S0090-4295(98)00492-0 Han, 2003, Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience, J Urol, 170, 1126, 10.1097/01.ju.0000087860.52991.a8 Katz A, Prepelica K, Masson P, Benson M, McKiernan J. Salvage cryosurgical ablation of the prostate for patients failing radiation: 10-year experience. Presented at 100th annual meeting of the American Urological Association, San Antonio, TX, 21–26 May (abstract no. 1129). Katz A, Prepelica K, McKiernan JM, Olsson CA, Benson MC. Salvage cryosurgical ablation of the prostate for patients failing radiation: efficacy and tolerability. Presented at 101st annual meeting of the American Urological Association, Atlanta, GA, 20–25 May (abstract no. 1132). Ghafar, 2001, Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience, J Urol, 166, 1333, 10.1016/S0022-5347(05)65763-1 Izawa, 2002, Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome, J Clin Oncol, 20, 2664, 10.1200/JCO.2002.06.086 Gelet, 2004, Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography, Urology, 63, 625, 10.1016/j.urology.2004.01.002 Ward, 2005, Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes, J Urol, 173, 1156, 10.1097/01.ju.0000155534.54711.60 Shipley, 2006, Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: a secondary analysis of RTOG protocol 86-10, Int J Radiat Oncol Biol Phys, 64, 1162, 10.1016/j.ijrobp.2005.09.039 Iversen, 2000, Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup, J Urol, 164, 1579, 10.1016/S0022-5347(05)67032-2 Wirth, 2004, Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer, Eur Urol, 45, 267, 10.1016/j.eururo.2003.10.013 Fourcade, 2004, Tolerability of antiandrogens in the treatment of prostate cancer, UroOncology, 4, 5, 10.1080/1561095042000191655 Aus G, Abbou CC, Bolla M, et al. European Association of Urology Guidelines on Prostate Cancer. Available at http://www.uroweb.nl/files/uploaded_files/2005Prostate%20Cancer.pdf. Accessed 19 December 2005. Sieber, 2004, Bicalutamide 150mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer, J Urol, 171, 2272, 10.1097/01.ju.0000127738.94221.da